What Is MT-1? Melanotan 1 Research Guide
What Is MT-1? Comprehensive Melanotan 1 Peptide Research Guide for Scientific Applications
Melanotan 1 (MT-1) is a synthetic peptide of interest to investigators studying pigmentation and immunomodulation. This guide furnishes a detailed synopsis of MT-1, addressing its chemical characteristics, biological interactions and documented research applications. Academic researchers and laboratory professionals consult such summaries to evaluate mechanisms of action and experimental utility. Given the increasing utilisation of research-grade peptides, a rigorous understanding of MT-1’s role in controlled studies is necessary. The content that follows examines MT-1’s chemical and biological properties, molecular structure, receptor interactions and recent pharmacodynamic findings.
Overview of Melanotan 1 (MT-1) Research
Melanotan 1, also designated afamelanotide, is a synthetic analogue of the endogenous hormone alpha-melanocyte-stimulating hormone (). It was developed to augment cutaneous melanin synthesis and has been investigated as a therapeutic strategy for conditions such as erythropoietic protoporphyria and other photodermatoses. MT-1’s significance in research derives from its capacity to stimulate melanogenesis—the cellular process of melanin production—thereby informing studies of skin protection and pigmentation disorders. A precise account of MT-1’s developmental context and experimental relevance is essential for investigators planning related protocols.
What Are the Chemical and Biological Properties of Melanotan 1 Peptide?
Melanotan 1 demonstrates chemical and biological characteristics that warrant experimental investigation.
The peptide sequence permits effective interaction with melanogenic cells, resulting in elevated melanin synthesis. Its biological activity is principally mediated via activation of melanocortin receptors, with MC1R playing a central role in cutaneous pigmentation and photoprotective responses.
What Is the Molecular Structure and Composition of MT-1?
MT-1 is a linear peptide comprising 13 amino acids. This defined sequence enables the molecule to mimic the activity of . The peptide’s molecular configuration underpins its interaction with melanin-producing cells and its efficacy in activating melanocortin receptors, rendering it a relevant reagent for studies of pigmentation and skin physiology.
How Does MT-1 Interact with Melanocortin Receptors?
MT-1 engages primarily with the melanocortin 1 receptor (MC1R), which is predominantly expressed in melanocytes. Ligand binding activates intracellular signalling cascades that increase eumelanin synthesis, the pigment associated with darker skin tones. MC1R activation by MT-1 also contributes to photoprotective mechanisms against ultraviolet radiation. Characterisation of this receptor–ligand interaction is essential for evaluating MT-1’s therapeutic potential in dermatological research.
What Are the Established Research Applications of MT-1 Peptide?
MT-1 has established utility in pigmentation research and in studies of immunomodulation. Key research applications include:
- Pigmentation Research: MT-1 is used to study the mechanisms of melanin production and its effects on skin health.
- Photoprotection Studies: Researchers investigate how MT-1 can enhance the skin’s resistance to UV damage.
- Receptor Biology: MT-1 serves as a model for understanding the signaling pathways activated by melanocortin receptors.
Collectively, these applications demonstrate MT-1’s utility for both fundamental and translational investigations.
How Is Melanotan 1 Used in Pigmentation and Immunomodulation Studies?
In pigmentation experiments, MT-1 is applied in cell-culture systems and animal models to quantify effects on melanin synthesis. Reported data indicate significant increases in melanin production, suggesting potential therapeutic approaches for conditions characterised by hypopigmentation. MT-1’s immunomodulatory properties are concurrently under investigation, specifically its capacity to influence immune responses in cutaneous cells. The combination of these activities supports continued research in pigmentation biology and cutaneous immunology.
What Recent 2024-2026 Studies Highlight MT-1 Pharmacodynamics?
Studies conducted between 2024 and 2026 have provided additional pharmacodynamic characterisation of MT-1. Results indicate that MT-1 enhances melanin synthesis and exhibits anti-inflammatory activity, which may contribute to reduced UV-induced skin damage. These observations support investigation of MT-1 in therapeutic strategies targeting inflammatory and pigmentary skin disorders. Continued research is required to delineate the complete pharmacological profile and translational potential.
Early investigations of MT-1’s effects on skin pigmentation established foundational pharmacodynamic parameters and characterised the temporal profile of the tanning response.
Melanotan-I Pharmacokinetics and Skin Pigmentation
SC dosing produced a peak pigmentary response one week after a 10‑day dosing regimen, with substantial fading observed by 30 days but not a complete loss of pigmentation.
Skin pigmentation and pharmacokinetics of melanotan‐I in humans, 1997
What Are the Recommended Dosage Guidelines and Safety Considerations for MT-1?
Use of MT-1 in research protocols requires strict adherence to established dosage ranges and safety procedures. Reported research dosages typically range from 0.5 to 1.0 mg per kilogram of body weight, administered subcutaneously. Investigators should account for inter-individual variability—factors such as age, comorbidities and genetic background can influence response. Study protocols must include monitoring measures to detect and manage adverse events.
What Dosage Protocols Are Used in Scientific Research for MT-1?
In controlled research settings, several dosing regimens are employed to characterise MT-1 effects precisely. Common protocols include:
- Initial Loading Dose: A higher initial dose to quickly achieve therapeutic levels.
- Maintenance Dose: A lower dose administered regularly to maintain the desired effects.
- Tapering Protocol: Gradually reducing the dose after achieving the desired outcomes to minimize potential side effects.
These regimens are intended to optimise experimental outcomes while minimising risk to study subjects within the parameters of approved research protocols.
What Are the Documented Side Effects and Safety Profiles of Melanotan 1?
MT-1 is generally well tolerated; however, documented adverse events have been reported. Common effects include:
- Nausea: Some individuals may experience gastrointestinal discomfort.
- Flushing: Temporary erythema or redness of the skin can occur following administration.
- Increased Appetite: Some subjects report elevated hunger.
Available long-term safety data suggest no significant adverse outcomes when MT-1 is used within recommended research dosages. Nevertheless, ongoing surveillance and systematic research are required to comprehensively define its safety profile.
How Is MT-1 Peptide Synthesized and Purified for Research Use?
MT-1 is synthesised using solid-phase peptide synthesis (SPPS), which permits precise sequential assembly of amino acids. Post-synthesis purification commonly employs high-performance liquid chromatography (HPLC) to remove impurities and achieve defined purity specifications. Rigorous synthesis and purification protocols are essential to maintain peptide integrity for experimental use.
Validated analytical methodologies, including HPLC assays, are critical for accurate quantification of MT-1 in biological matrices and for ensuring data reliability.
HPLC Assay for Melanotan-1 in Biological Samples
MT-1 analysis in cell-culture transport buffer was achievable without prior sample clean-up; for plasma matrices, a solid-phase extraction step was implemented.
High-performance liquid chromatographic assay for melanotan-1 ([Nle4-DPhe7] α-melanocyte-stimulating hormone) in biological matrices, 1995
Where and How Can Researchers Purchase and Handle Research-Grade MT-1 Peptide?
Researchers may procure research-grade MT-1 from specialised suppliers. VivePeptides supplies MT-1 (Melanotan 1) to qualified researchers and academic institutions; the listed price is approximately $50.00 for 10 mg. Procurement should be accompanied by adherence to supplier specifications and established laboratory handling procedures to preserve peptide stability and experimental validity.
What Are the Specifications and Compliance Standards for MT-1 Products?
MT-1 products must conform to defined specifications and compliance standards to ensure quality and safety. Key parameters include:
- Purity Standards: MT-1 should have a minimum purity of 95% to be considered suitable for research.
- Quality Assurance Measures: Regular testing and validation of products are essential to maintain compliance with research standards.
Compliance with these specifications is essential to ensure experimental reproducibility and data integrity.
How Should MT-1 Be Properly Reconstituted and Stored for Research?
Proper reconstitution and storage are critical to preserve MT-1 stability and activity. Recommended laboratory practices include:
- Reconstitution: Dissolve MT-1 in sterile water or an appropriate buffer to achieve the required concentration.
- Storage Conditions: Store reconstituted MT-1 at −20°C to limit degradation and preserve potency.
- Handling Protocols: Employ aseptic technique during reconstitution and handling to prevent contamination.
Adherence to these procedures preserves peptide integrity and supports reliable experimental outcomes.
To further support research workflows, Bacteriostatic Water is specified for peptide reconstitution and can assist in maintaining the integrity of preparations.
For investigators evaluating additional peptides, BPC-157 is available and has been investigated for potential effects on healing and recovery in preclinical research.
